In conclusion, as discussed so far and illustrated in Table 2, biomarkers such as PIK3CA mutational status, BRCA1/2 mutations, TILs, and ctDNA have demonstrated considerable promise in predicting therapeutic responses and survival outcomes, particularly in TNBC and HER2-positive breast cancers. Here, ERBB2 is linked to breast carcinoma.